Bariatric Fusion GLP-ONE + Receptor Activator
GLP-ONE pairs hops extract standardised to 20% xanthohumol with copaiba extract standardised to 10% beta-caryophyllene, at $29.99 for 30 capsules. The underlying mechanism — bitter compounds in the gut prompting your own L-cells to release GLP-1 — is real and has small human trials behind it. The name and much of the copy describe something else entirely, and the difference matters more than any other point on this page.
Last reviewed · researched from the manufacturer’s published pages by Tom
What’s in it
Amounts are shown only where the manufacturer publishes them. Anything without a figure is undisclosed — and for an active ingredient, an undisclosed dose is the central problem with this category.
- Hops extract (20% xanthohumol)Amount not published on the page we captured
Standardisation is published; the quantity is not
- Copaiba extract (10% beta-caryophyllene)Amount not published on the page we captured
Beta-caryophyllene is a CB2 receptor agonist
- Cellulose, rice bran lipid, ascorbyl palmitate, silicaamount not published
Other ingredients, as published
- Vegetarian capsule (cellulose)amount not published
Capsule shell
How the manufacturer says it works
Bariatric Fusion states the product 'promotes GLP-1 receptor activation, releasing GLP-1 hormone', describes it as delivering plant-derived ingredients to the gut for 'broad receptor activation' without injectables, and says the formula 'activates GLP-1 and CB2 receptors'. One sentence on the same page describes it more accurately as supporting the activation of GLP-1 and BITTER receptors. The page also answers 'yes' to whether it can be taken alongside a prescription GLP-1.
What the evidence actually supports
The real mechanism here is more interesting than the marketing. Bitter compounds reaching the gut activate bitter taste receptors on intestinal cells, which can prompt release of your own GLP-1 from L-cells — and hops extract specifically has small published human trials on appetite and energy intake using that pathway. Beta-caryophyllene is a genuine CB2 receptor agonist, which is established pharmacology. Publishing the standardisation percentages for both botanicals is better than naming them vaguely, the other-ingredients list is published, the directions are specific and sensible (after a main meal, never on an empty stomach), and there is a 100% satisfaction guarantee.
Where that evidence stops
Now the problem, and it is the central one. 'GLP-1 receptor activation' describes what semaglutide and tirzepatide do: bind and activate the GLP-1 receptor pharmacologically. This product does not do that, and the proposed mechanism is the opposite end of the process — bitter receptors prompting your own gut to secrete a little more GLP-1. The page contains the accurate version in one sentence and the misleading version in the product name and several others. The distinction is not pedantry: it is the difference between a drug effect and a small physiological nudge, and the name 'Receptor Activator' points the reader at the wrong one. Beyond that, no quantity is published for either botanical, so nothing can be checked against the hops trials. And the page answering 'yes' to combining it with a prescription GLP-1 is a decision for your prescriber, not a product FAQ.
Strengths and problems
Strengths
- Publishes standardisation percentages for both botanicals — 20% xanthohumol and 10% beta-caryophyllene
- The underlying bitter-receptor mechanism is real, and hops extract has small published human trials on appetite
- Publishes the full other-ingredients list
- Specific, sensible directions: after a main meal, never on an empty stomach
- 100% satisfaction guarantee
- One capsule daily at roughly $1 a day is straightforward
Problems
- The name and much of the copy say 'GLP-1 receptor activation', which is what the prescription drugs do and is not what this does
- The accurate description — bitter receptors prompting your own GLP-1 secretion — appears once, while the misleading one is in the product name
- No quantity published for either botanical, so nothing can be compared against the hops trials
- The page answers 'yes' to combining it with a prescription GLP-1; that is a prescriber's call, not a product FAQ's
- No third-party testing statement
- Free shipping threshold of $100 is high for a $29.99 product
What the manufacturer publishes
Publishes 8 of 8 standard terms.
- Intended use
- Sold as a dietary supplement, not as a treatment for any condition.
- Directions
- Take one capsule after a main meal, or as directed by a healthcare practitioner. The company states it should not be taken on an empty stomach.
- Warnings
- Not published on the page we captured beyond the instruction not to take it on an empty stomach.
- Allergens
- Not published on the page we captured. Vegetarian capsule.
- Third-party testing
- Not stated on the page we captured.
- Pricing
- $29.99 for 30 capsules — a one-month supply at one capsule daily, so roughly $1 a day.
- Subscription
- Not stated on the page we captured.
- Refunds
- States a 100% satisfaction guarantee.
- Shipping
- Free shipping on orders over $100.
May suit
Someone interested in the bitter-receptor appetite pathway who will read past the product name and ask for the actual milligram amounts.
Do not use if
- You are taking a prescription GLP-1 and have not asked your prescriber about adding this
- You are pregnant or breastfeeding — hops has hormonal activity
- You would read 'Receptor Activator' as meaning it works like semaglutide
- You take sedatives — hops is traditionally used for sedation and the interaction is not addressed on the page
Frequently asked
Does it activate the GLP-1 receptor like Ozempic?
No. That phrasing is the problem with this label. Semaglutide binds and activates the GLP-1 receptor directly and continuously. The mechanism proposed for these botanicals is bitter receptors in your gut prompting your own cells to release a little more GLP-1 — the far end of the same system, at a far smaller scale. The company's own page states the accurate version once. The product name states the misleading one.
Is the hops research real?
Yes, and it is the most interesting thing here. Hops extract has small published human trials on appetite and energy intake through the bitter receptor pathway. The difficulty is that no amount is published for this product, so there is no way to know whether it matches what was studied.
Can I take it with my prescription GLP-1?
The page says yes. We would not treat that as an answer. Adding anything with metabolic or appetite activity on top of a prescription GLP-1 is a conversation for the clinician managing your dose.
Sources
Captured . Manufacturer pages change — check the current version before relying on anything.